IFNA2 and COVID-19: The proportion of critical COVID-19 patients with auto-Abs neutralizing 10 ng/mL IFN-α2 and/or IFN-ω increased continuously, with auto-Abs detected in 5% of patients under the age of 40 years, 6.8% of those between 40 and 49 years of age, 7.1% of those between 50 and 59 years of age, 10.7% of those between 60 and 69 years of age, 12.3% of those between 70 and 79 years, and almost 14% in those over 80 (Fig. 3C-F, S3B-I).